Cargando…

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

Detalles Bibliográficos
Autores principales:	Siccardi, M, D'Avolio, A, Baietto, L, Simiele, M, Bonora, S, Back, DJ, Di Perri, G, Owen, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112958/ http://dx.doi.org/10.1186/1758-2652-13-S4-P178

Ejemplares similares

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
por: Calcagno, A, et al.
Publicado: (2010)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Anti-inflammatory effect of procalcitonin on in vitro LPS-stimulated human PBMC
por: Foca, A, et al.
Publicado: (2010)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Does the number of apoptotic cells in PBMC reveal the extent of impairment in T cell functionality?
por: Sundararaman, Srividya, et al.
Publicado: (2013)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
por: Baietto, Lorena, et al.
Publicado: (2014)

P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC
por: Chenine, A, et al.
Publicado: (2009)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis
por: Zolopa, A, et al.
Publicado: (2010)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
por: Baudry, T, et al.
Publicado: (2010)

Multicolor flow cytometry analysis of innate responses following in vitro interaction of PBMC with Hepatitis C virus
por: Gondois-Rey, Françoise, et al.
Publicado: (2010)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

Tuberculosis After Gastrectomy, Plasmatic Concentration of Antitubercular Drugs
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2012)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study
por: Meijide, Héctor, et al.
Publicado: (2010)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2013)

Penetrating cardiac injury
por: Tahalele, PL, et al.
Publicado: (2013)

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010)

Optimization of ex vivo expansion of HER2 specific polyfunctional Th1/Th17 cells from HER2 vaccine primed PBMC
por: Dang, Yushe, et al.
Publicado: (2013)

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
por: Izzo, I, et al.
Publicado: (2010)

Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?
por: Seden, K, et al.
Publicado: (2010)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Expression of cytokine-mRNA in PBMC of HIV-1 subtype C infected individuals with opportunistic viral infections from South India
por: Sachithanandham, Jaiprasath, et al.
Publicado: (2014)

Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma
por: Dennis, Lucas, et al.
Publicado: (2015)

Ambulance transport is associated with a higher mortality than private transport following major penetrating trauma in a semi-urban environment
por: Dickson, E, et al.
Publicado: (2007)

Cerebrospinal fluid penetration of linezolid in neurosurgical patients
por: Myrianthefs, P, et al.
Publicado: (2006)

P11-13. Antigen presentation and immune priming of CCR5-ECL1 receptor in Peyer's patches B cells
por: Lopalco, L, et al.
Publicado: (2009)

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
por: Walimbwa, Stephen I., et al.
Publicado: (2021)

Right ventricular thrombus after penetrating cardiac injury
por: Nenadić, D, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_leaqui7g8urdv1b8gjtvjn292h